Investor Carl Icahn notified Biogen Idec about his plan to nominate three people to the biotech firm's board of directors. Two of the nominees helped Icahn take control of and sell ImClone Systems to Eli Lilly and Co. in 2006. Biogen said it will review Icahn's proposal and decide based on the interests of shareholders.

Full Story:

Related Summaries